BARCELONA, Spain ― Using 177 Lu-PSMA (prostate-specific membrane antigen) SPECT to monitor tumor response at week 12 after the third dose of the targeted radioligand 177 Lu-PSMA-617 (Pluctivo, ...
Monitoring early-response biomarkers in patients receiving lutetium-177 (177 Lu)–PSMA-617 for metastatic castrate-resistant prostate cancer may allow physicians to personalize dosing intervals and ...
In a study presented at the Society of Nuclear Medicine and Molecular Imaging 2023 Annual Meeting, early stratification with 177 Lu-SPECT/CT allowed men responding to treatment to take a "treatment ...
A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently and reliably assess prostate cancer progression or regression during treatment. With this strong ...
Approved by the U.S. Food and Drug Administration in 2022, 177 Lu-PSMA is an effective treatment for metastatic castration-resistant prostate cancer. However, not all men respond equally to treatment, ...
Researchers at the University of Washington in Seattle, Washington, are developing a user-friendly (worn at home) vest with technology that collects data to tailor personalized therapy for patients ...
CHICAGO & VANCOUVER, British Columbia--(BUSINESS WIRE)--GE Healthcare is proud to provide cutting-edge molecular imaging solutions that enable and increase access to precision health and theranostics ...
ISTANBUL--(BUSINESS WIRE)--Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has today announced it has signed an agreement with Curium Netherlands B.V (Curium) to license its GMP grade medical ...
Next-generation fusion specialist SHINE Technologies has secured centralised marketing authorisation (CMA) in Europe for its radioisotope product Ilumira (non-carrier-added lutetium-177), allowing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results